ADC Therapeutics registers 27,726,052 shares

ADC Therapeutics SA updates its prospectus to confirm that 27,726,052 common shares remain registered for resale by selling shareholders under the prospectus dated July 9, 2025.

Rhea-AI Filing Summary

ADC Therapeutics SA updates its prospectus to confirm that 27,726,052 common shares remain registered for resale by selling shareholders under the prospectus dated July 9, 2025. The supplement dated April 15, 2026 registers a transfer of 1,383,144 shares from Point72 Associates, LLC to SILV Fund Ltd., reducing Point72’s offering by that amount and adding SILV Fund Ltd. as a selling shareholder; the aggregate registered amount is unchanged.

Key Figures

Registered shares: 27,726,052 shares Transferred shares: 1,383,144 shares Prospectus date: July 9, 2025 +2 more

5 metrics

Registered shares 27,726,052 shares registered for resale per prospectus dated July 9, 2025

Transferred shares 1,383,144 shares transferred from Point72 Associates, LLC to SILV Fund Ltd.

Prospectus date July 9, 2025 original prospectus date referenced in supplement

Supplement date April 15, 2026 date of this prospectus supplement

SILV Fund beneficial ownership prior 1,383,144 shares number of common shares beneficially owned prior to any sale (as listed)

Key Terms

prospectus supplement, selling shareholders, beneficially owned

3 terms

prospectus supplement regulatory

"This prospectus supplement updates ADC Therapeutics SA’s prospectus dated July 9, 2025"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

selling shareholders financial

"offer and sale from time to time by the selling shareholders of 27,726,052 common shares"

Shareholders who are offering some or all of their shares for sale in a market transaction or as part of an offering; they can be founders, early investors, employees, or other holders deciding to convert ownership into cash. Investors care because selling shareholders can change the ownership mix, increase the number of shares available to trade, and signal insiders’ confidence or need for liquidity—like a large owner putting a big parcel on the market, which can affect price and voting control.

beneficially owned regulatory

"Number of Common Shares Beneficially Owned Prior to Any Sale"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change does the ADCT prospectus supplement make?

It registers a transfer of 1,383,144 shares to SILV Fund Ltd. The supplement reduces Point72 Associates’ offering by 1,383,144 shares and adds SILV Fund Ltd. as a selling shareholder while keeping the aggregate registered amount at 27,726,052 shares.

How many shares are registered for resale under ADCT’s prospectus?

A total of 27,726,052 common shares are registered for resale. That aggregate amount was established by the prospectus dated July 9, 2025 and remains unchanged by this supplement dated April 15, 2026.

Who now appears as a selling shareholder after the supplement?

SILV Fund Ltd. is newly listed as a selling shareholder for 1,383,144 shares. The filing states Sirenia Capital Management LP is the fund’s investment manager and provides the fund’s address in Miami Beach, Florida.

Does the supplement change the total number of registered shares for ADCT?

No, the supplement does not change the aggregate registered amount. It reallocates 1,383,144 registered shares from Point72 Associates, LLC to SILV Fund Ltd., leaving the total at 27,726,052 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:20 PM EDT Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)
Registration No. 333-288437

PROSPECTUS SUPPLEMENT NO. 1
(TO PROSPECTUS DATED JULY 9, 2025)

This prospectus supplement updates ADC Therapeutics SA’s (the “Company”) prospectus dated July 9, 2025 relating to the offer and sale from time to time by the selling shareholders of 27,726,052 common shares. This prospectus supplement should be read in conjunction with the prospectus and is not complete without, and may not be used or delivered except in connection with, the prospectus.

Point72 Associates, LLC, a selling shareholder named in the prospectus, has informed the Company that it transferred 1,383,144 common shares registered pursuant to the prospectus to SILV Fund Ltd. This prospectus supplement updates the table contained in the “Selling Shareholders” section of the prospectus by (i) reducing the number of common shares that may be offered and sold by Point72 Associates, LLC by 1,383,144 common shares and (ii) adding SILV Fund Ltd. as a selling shareholder as set forth below to register the offer and sale by SILV Fund Ltd. of the 1,383,144 common shares that it received from Point72 Associates, LLC. This prospectus supplement does not change the aggregate number of shares registered pursuant to the prospectus.

Selling Shareholder	Number of Common Shares Beneficially Owned Prior to Any Sale	Number of Common Shares Offered by this Prospectus	Number of Common Shares Beneficially Owned Assuming Sale of All Shares Offered by this Prospectus
SILV Fund Ltd.(1)	1,383,144	1,383,144	—

(1)       Sirenia Capital Management LP (“Sirenia”) is the investment manager of SILV Fund, Ltd. and as such has investment and voting power with respect to the securities held by SILV Fund, Ltd. Sirenia Capital Management GP LLC (“Sirenia GP”) is the general partner of Sirenia. Alex Silverstein is the managing member of Sirenia GP. Each of SILV Fund, Ltd., Sirenia GP and Mr. Silverstein disclaims beneficial ownership over such securities. The address for the selling shareholder is 1674 Meridian Ave, Suite 320, Miami Beach, FL 33139.

Prospectus supplement dated April 15, 2026.